|
May 3
|
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
|
|
May 3
|
Amgen Knocks Novo Nordisk's Ozempic Stock Rally. Its Stock Is Flying.
|
|
May 3
|
FTC Seeks More Information on $16.5 Billion Novo-Catalent Deal
|
|
May 3
|
US FTC seeks more information on Novo Nordisk parent-Catalent deal
|
|
May 3
|
UPDATE 2-US FTC seeks more information on Novo Nordisk parent-Catalent deal
|
|
May 3
|
Novo Slides as Amgen Fuels Obesity Drug Competition Fears
|
|
May 3
|
How the CFOs of Eli Lilly and Novo Nordisk are coping with ‘unprecedented demand’ for weight-loss drugs
|
|
May 3
|
This Is a Huge Sigh of Relief for Novo Nordisk Investors
|
|
May 3
|
Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data
|
|
May 3
|
Here’s How Novo Holdings’ Catalent (CTLT) Acquisition Affects Laughing Water Capital
|
|
May 2
|
Weight Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro
|
|
May 2
|
Novo Nordisk slides while Moderna pops: Tale of two pharma stocks
|
|
May 2
|
Market Chatter: Novo Nordisk, Eli Lilly's Weight-Loss Drugs Get Price Cuts in UK
|
|
May 2
|
Novo Nordisk Dips After Wegovy Sales Double, But Miss Analysts' Forecast
|
|
May 2
|
Novo Nordisk’s Wegovy Sales More Than Doubled. Why the Stock Is Falling.
|
|
May 2
|
Novo Nordisk (NVO) Q1 2024 Earnings Call Transcript
|
|
May 2
|
Novo Nordisk sales up 26% driven by GLP-1s, misses 11% on Wegovy
|
|
May 2
|
Top Midday Stories: Novo Nordisk, Linde Shares Fall Post-Earnings; Peloton Shares Plummet After Announcing Job Cuts, CEO Change; Exxon-Pioneer Deal Gets FTC Approval With One Caveat
|
|
May 2
|
Novo Nordisk Stock Falls After Pricing Pressure Mounts for Wegovy
|
|
May 2
|
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
|